Allianz Asset Management
IBRX icon

Allianz Asset Management’s ImmunityBio IBRX Stock Holding History

Allianz Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
25,600
-21,800
-46% -$165K ﹤0.01% 2080
2026
Q1 		$364K Buy
+47,400
New +$324K ﹤0.01% 1878
2024
Q3 		– Sell
-25,000
Closed -$158K – 2226
2024
Q2 		$158K Buy
+25,000
New +$165K ﹤0.01% 2042

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allianz Asset Management's IBRX Position: Q2 2026 in Review

Allianz Asset Management reduced its ImmunityBio (IBRX) stake by 46% in Q2 2026, selling an estimated $165K and leaving 25,600 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

Allianz Asset Management first reported a position in IBRX in Q2 2024 and has held it in 3 quarters since. The position peaked at $364K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Allianz Asset Management held 25,600 shares of ImmunityBio worth $224K as of Q2 2026.
  • Allianz Asset Management sold 21,800 ImmunityBio shares in Q2 2026, an estimated $165K.
  • ImmunityBio made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2080 holding.
  • Allianz Asset Management first reported a position in ImmunityBio in Q2 2024 and has held it in 3 quarters since.
  • Allianz Asset Management's ImmunityBio position peaked at $364K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.